H1N1 Test With Affymetrix Technology Gets FDA Approval
December 21 2009 - 10:02AM
Dow Jones News
Affymetrix Inc. (AFFX) and TessArae LLC said the Food and Drug
Administration has granted emergency use authorization for a H1N1
influenza detection panel.
Shares rose 9.6% premarket to $6.08. The stock has nearly
doubled this year.
The product was created by privately held TessArae using
technology from Affymetrix, which makes products to help analyze
genetic information.
TessArae's product isn't the only one to receive such emergency
clearance from the FDA for H1N1 detection, but the company said one
of its product's unique aspects is that it "directly generates
genomic sequence from multiple influenza virus genes" to identify
the particular H1N1 virus strain in a single test.
-By Kevin Kingsbury; Dow Jones Newswires; 212-416-2354; kevin.kingsbury@dowjones.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Apr 2023 to Apr 2024